samedan logo

 
 
spacer
home > about us
Samedan Ltd. Pharmaceutical Publishers

Specialist pharmaceutical publisher Samedan Ltd is a dynamic, forward-thinking company, enjoying year-on-year growth with its five market-leading titles for industry professionals: European Pharmaceutical Contractor, Pharmaceutical Manufacturing and Packing Sourcer, European Biopharmaceutical Review, Innovations in Pharmaceutical Technology, and International Clinical Trials.

In 2013, the company extended its range with the acquisition of the Pharmafile portfolio, consisting of Pharmafocus newspaper, www.pharmafile.com, and Pharmafile directory. The London-based company has been producing a wide range of magazines for the global pharmaceutical arena since 1996, covering a wide range of hot topics including R&D, clinical trials, cutting-edge technology, manufacture, packaging, logistics, regulations, and industry insight.

Located in an idyllic region synonymous with culture and quality, the Alpine village of Samedan is renowned for its tradition of hospitality and shares many of its ideals with the company it inspired. Samedan hopes to develop its ties with the industry further still and maintains a fresh vision for the future.

spacer

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

News and Press Releases

Novo Nordisk to Acquire Emisphere Technologies for $1.35 Billion

ROSELAND, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced that it has entered into a definitive agreement with Novo Nordisk A/S (“Novo Nordisk”), whereby Novo Nordisk will acquire Emisphere, on a cash-free, debt-free basis, for $1.35 billion in cash. The consideration to be paid per share will depend on the amount of cash and debt at closing, but the Company currently estimates it to be approximately $7.82 per share based on approximately 170.9 million fully diluted shares outstanding. This price represents a premium of approximately 17% over the volume-weighted average Emisphere share price for the five trading days ending on November 5, 2020.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement